{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:51:19Z","timestamp":1789437079756,"version":"build-2803163510"},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"Background:<\/jats:bold> The objectives of this study were to determine whether frailty is associated with survival in a population-based sample of patients with diffuse large B-cell lymphoma (DLBCL) and to describe the healthcare utilization patterns of frail versus nonfrail patients during treatment. Methods:<\/jats:bold> A retrospective cohort study was conducted using population-based data in Ontario, Canada. Patients aged \u226566 years diagnosed between 2006 and 2017 with DLBCL or transformed follicular lymphoma who received first-line curative-intent chemoimmunotherapy were included. Frailty was defined using a modified version of a generalizable frailty index developed for use with Ontario administrative data. Cox regression was performed to examine the association between frailty and 1-year mortality. Results:<\/jats:bold> A total of 5,527 patients were included (median age, 75 years [interquartile range, 70\u201380 years]; 48% female), of whom 2,699 (49%) were classified as frail. Within 1 year of first-line treatment, 32% (n=868) of frail patients had died compared with 20% (n=553) of nonfrail patients (unadjusted hazard ratio, 1.8; 95% CI, 1.6\u20132.0; P<\/jats:italic><.0001). Frail patients had higher healthcare utilization during treatment, with most hospitalizations related to infection and\/or lymphoma. In multivariable modeling controlling for age, inpatient diagnosis, number of chemoimmunotherapy cycles received, comorbidity burden, and healthcare utilization, frailty remained independently associated with 1-year mortality (adjusted hazard ratio, 1.5; 95% CI, 1.3\u20131.7; P<\/jats:italic><.0001). Conclusions:<\/jats:bold> In a population-based sample of older adult patients with DLBCL receiving front-line curative-intent therapy, half were classified as frail, and their adjusted relative rate of death in the first year after starting treatment was 50% higher than that of nonfrail patients. Frailty seems to be associated with poor treatment tolerance and a higher likelihood of requiring acute hospital-based care.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7014","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T18:17:27Z","timestamp":1655489847000},"page":"635-642.e9","source":"Crossref","is-referenced-by-count":13,"title":["Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study"],"prefix":"10.6004","volume":"20","author":[{"given":"Abi","family":"Vijenthira","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre,"},{"name":"2Department of Medicine, University of Toronto,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Mozessohn","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Toronto,"},{"name":"3Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, and"},{"name":"4Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenthila","family":"Nagamuthu","sequence":"additional","affiliation":[{"name":"4Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"4Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Blunt","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir","family":"Alibhai","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Toronto,"},{"name":"6Division of General Internal Medicine and Geriatrics, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre,"},{"name":"2Department of Medicine, University of Toronto,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Toronto,"},{"name":"3Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, and"},{"name":"4Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/6\/article-p635.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/6\/article-p635.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T18:17:27Z","timestamp":1655489847000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/6\/article-p635.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":0,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7014","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}